胶质母细胞瘤的放射治疗:美国临床肿瘤学会对ASTRO指南的临床实践指南背书
美国临床肿瘤学会(ASCO)对ASTRO于2016年发布的胶质母细胞瘤放射治疗指南进行方法学严格性和内容审查,更新文献检索后认为该指南推荐清晰、全面且基于当前科学证据,予以背书并添加限定性声明。
要点
- 对于新诊断胶质母细胞瘤,年龄≤70岁患者经活检或切除后,部分脑放射治疗联合同步及辅助替莫唑胺是标准治疗。
- 体能状态尚可至良好的老年患者适合大分割放射治疗,联合替莫唑胺似乎安全有效且不损害生活质量。
- 体能状态差的患者可选择单纯大分割放射治疗、单纯替莫唑胺或最佳支持治疗。
核心结论
- ASCO背书小组认定ASTRO于2016年发布的胶质母细胞瘤放射治疗指南推荐清晰、全面且基于当前科学证据,予以背书并添加限定性声明。
研究设计与样本
- ASCO方法学家对ASTRO胶质母细胞瘤放射治疗指南的开发严谨性进行审查,ASCO背书小组更新文献检索并审查内容和推荐。
主要发现
- ASCO背书小组认定ASTRO指南的推荐清晰、全面且基于当前科学证据。
- ASCO背书了ASTRO胶质母细胞瘤放射治疗指南并添加限定性声明。
关键数值与推荐
- 对于年龄≤70岁新诊断胶质母细胞瘤患者,经活检或切除后,部分脑放射治疗联合同步及辅助替莫唑胺是标准治疗。
- 对于体能状态尚可至良好的老年患者,大分割放射治疗是合适的。
- 对于体能状态良好的老年患者,大分割放射治疗联合同步及辅助替莫唑胺似乎安全有效且不损害生活质量。
- 对于体能状态差的患者,合理选项包括单纯大分割放射治疗、单纯替莫唑胺或最佳支持治疗。
- 对于复发胶质母细胞瘤的部分患者,局灶性再程放疗是一个选择,但缺乏前瞻性随机证据支持。
临床怎么用
- 对于年龄≤70岁新诊断胶质母细胞瘤患者,经活检或切除后,应采用部分脑放射治疗联合同步及辅助替莫唑胺作为标准治疗。
- 对于体能状态尚可至良好的老年患者,可考虑大分割放射治疗;体能状态良好者联合替莫唑胺似乎安全有效。
- 对于体能状态差的患者,合理选项包括单纯大分割放射治疗、单纯替莫唑胺或最佳支持治疗。
- 对于复发胶质母细胞瘤的部分患者,局灶性再程放疗是一个选择,但缺乏前瞻性随机证据支持。
局限性
- 局灶性再程放疗作为复发胶质母细胞瘤的选择,缺乏前瞻性随机证据支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy for glioblastoma. Because of its relevance to the ASCO membership, ASCO reviewed the guideline and applied a set of procedures and policies used to critically examine guidelines developed by other organizations. Methods The ASTRO guideline on radiation therapy for glioblastoma was reviewed for developmental rigor by methodologists. An ASCO endorsement panel updated the literature search and reviewed the content and recommendations. Results The ASCO endorsement panel determined that the recommendations from the ASTRO guideline, published in 2016, are clear, thorough, and based on current scientific evidence. ASCO endorsed the ASTRO guideline on radiation therapy for glioblastoma and added qualifying statements. Recommendations Partial-brain fractionated radiotherapy with concurrent and adjuvant temozolomide is the standard of care after biopsy or resection of newly diagnosed glioblastoma in patients up to 70 years of age. Hypofractionated radiotherapy for elderly patients with fair to good performance status is appropriate. The addition of concurrent and adjuvant temozolomide to hypofractionated radiotherapy seems to be safe and efficacious without impairing quality of life for elderly patients with good performance status. Reasonable options for patients with poor performance status include hypofractionated radiotherapy alone, temozolomide alone, or best supportive care. Focal reirradiation represents an option for select patients with recurrent glioblastoma, although this is not supported by prospective randomized evidence. Additional information is available at www.asco.org/glioblastoma-radiotherapy-endorsement and www.asco.org/guidelineswiki .
引用
- Sulman EP, Ismaila N, Armstrong TS, et al. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. J Clin Oncol. 2016. PMID: 27893327. doi:10.1200/JCO.2016.70.7562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。